Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of INCA033989 alone or with ruxolitinib in myeloproliferative neoplasms
jRCT2031230426Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of inca033989 and ruxolitinib in myeloproliferative disorder (MPD), myelofibrosis (MF) and thrombocythemia (8 arms), sponsored by Incyte. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with treatment-emergent adverse events and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
inca033989ruxolitinib
03
Conditions
myeloproliferative disorder (MPD)myelofibrosis (MF)thrombocythemia
Beyond the preview
Go deeper on jRCT2031230426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230426.